• 1
    Canadian cancer statistics 2004. Toronto: National Cancer Institute of Canada; 2004.
  • 2
    Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 829.
  • 3
    Chambers AF. The metastatic process: basic research and clinical implications. Oncol Res 1999; 11: 161168.
  • 4
    Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563572.
  • 5
    Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 6166.
  • 6
    Chambers AF, Naumov GN, Varghese HJ, Nadkarni KV, MacDonald IC, Groom AC. Critical steps in hematogenous metastasis: an overview. Surg Oncol Clin N Am 2001; 10: 243255.
  • 7
    Fidler IJ. 7th Janunary Waldenstrom Lecture. The biology of human cancer metastasis. Acta Oncol 1991; 30: 668675.
  • 8
    MacDonald IC, Groom AC, Chambers AF. Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays 2002; 24: 885893.
  • 9
    Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997; 80( suppl): 15291537.
  • 10
    Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448456.
  • 11
    Swartz MA, Skobe M. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 2001; 55: 9299.
  • 12
    Simpson SJ, Vachula M, Kennedy MJ, Kaizer H, Coon JS, Ghalie R, Williams S, Van Epps D. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol 1995; 23: 10621068.
  • 13
    Pachmann K, Heiss P, Demel U, Tilz G. Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC). Clin Chem Lab Med 2001; 39: 811817.
  • 14
    Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and others. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781791.
  • 15
    Aerts J, Wynendaele W, Paridaens R, Christiaens MR, van den Bogaert W, van Oosterom AT, Vandekerckhove F. A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol 2001; 12: 3946.
  • 16
    Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997; 278: 10541059.
  • 17
    Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, Provencio M, Espana P, Bonilla F. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res 2001; 7: 28212825.
  • 18
    Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE, Hoon DS. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res 2001; 61: 88458850.
  • 19
    Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van' t Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 2003; 88: 10911094.
  • 20
    Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N and others. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002; 20: 34043412.
  • 21
    Garber K. Trial results boost circulating tumor cell field. J Natl Cancer Inst 2004; 96: 10551057.
  • 22
    Ring A, Smith IE, Dowsett M. Circulating tumour cells in breast cancer. Lancet Oncol 2004; 5: 7988.
  • 23
    Brandt BH, Schmidt H, de Angelis G, Zanker KS. Predictive laboratory diagnostics in oncology utilizing blood-borne cancer cells—current best practice and unmet needs. Cancer Lett 2001; 162( suppl): S11S16.
  • 24
    Brunner N, Boysen B, Romer J, Spang-Thomsen M. The nude mouse as an in vivo model for human breast cancer invasion and metastasis. Breast Cancer Res Treat 1993; 24: 257264.
  • 25
    Phillips RA, Jewett MA, Gallie BL. Growth of human tumors in immune-deficient scid mice and nude mice. Curr Top Microbiol Immunol 1989; 152: 259263.
  • 26
    Hendrickson EA. The SCID mouse: relevance as an animal model system for studying human disease. Am J Pathol 1993; 143: 15111522.
  • 27
    Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumour growth and metastasis in beige mice. Nature 1980; 284: 622624.
  • 28
    Clarke R. Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 1996; 39: 6986.
  • 29
    Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717721.
  • 30
    Price JE, Zhang RD. Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev 1990; 8: 285297.
  • 31
    Welch DR. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997; 15: 272306.
  • 32
    Cailleau R, Young R, Olive M, Reeves WJ, Jr. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974; 53: 661674.
  • 33
    Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 14091416.
  • 34
    Band V, Zajchowski D, Swisshelm K, Trask D, Kulesa V, Cohen C, Connolly J, Sager R. Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res 1990; 50: 73517357.
  • 35
    Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999; 18: 42374246.
  • 36
    Sen S. Aneuploidy and cancer. Curr Opin Oncol 2000; 12: 8288.
  • 37
    Baker M, Gillanders WE, Mikhitarian K, Mitas M, Cole DJ. The molecular detection of micrometastatic breast cancer. Am J Surg 2003; 186: 351358.
  • 38
    Ambros PF, Mehes G, Ambros IM, Ladenstein R. Disseminated tumor cells in the bone marrow—chances and consequences of microscopical detection methods. Cancer Lett 2003; 197: 2934.
  • 39
    Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S. Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 2003; 9: 63266334.
  • 40
    Moll R. Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 1994; 9: 6369.
  • 41
    Traweek ST, Liu J, Battifora H. Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. Am J Pathol 1993; 142: 11111118.
  • 42
    Krismann M, Todt B, Schroder J, Gareis D, Muller KM, Seeber S, Schutte J. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995; 13: 27692775.
  • 43
    Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G, Riethmuller G, Pantel K. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997; 15: 27012708.
  • 44
    Lambrechts AC, Bosma AJ, Klaver SG, Top B, Perebolte L, van' t Veer LJ, Rodenhuis S. Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Res Treat 1999; 56: 219231.
  • 45
    Wingren S, Guerrieri C, Franlund B, Stal O. Loss of cytokeratins in breast cancer cells using multiparameter DNA flow cytometry is related to both cellular factors and preparation procedure. Anal Cell Pathol 1995; 9: 229233.
  • 46
    Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996; 2: 18791885.
  • 47
    Fuchs IB, Lichtenegger W, Buehler H, Henrich W, Stein H, Kleine-Tebbe A, Schaller G. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 2002; 22: 34153419.
  • 48
    Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H, Mikulits W. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 2004; 566: 920.
  • 49
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442454.
  • 50
    Sommers CL, Walker-Jones D, Heckford SE, Worland P, Valverius E, Clark R, McCormick F, Stampfer M, Abularach S, Gelmann EP. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res 1989; 49: 42584263.
  • 51
    Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83: 249289.
  • 52
    Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991; 2: 4754.
  • 53
    Maiorana A, Cesinaro AM, Fano RA, Collina G. Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases. Clin Exp Metastasis 1995; 13: 4348.
  • 54
    Redondo M, Garcia J, Villar E, Rodrigo I, Perea-Milla E, Serrano A, Morell M. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 2003; 34: 12831289.
  • 55
    Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003; 195: 346355.
  • 56
    Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmuller G. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991; 51: 47124715.
  • 57
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 58
    Gross HJ, Verwer B, Houck D, Recktenwald D. Detection of rare cells at a frequency of one per million by flow cytometry. Cytometry 1993; 14: 519526.
  • 59
    Naume B, Borgen E, Beiske K, Herstad TK, Ravnas G, Renolen A, Trachsel S, Thrane-Steen K, Funderud S, Kvalheim G. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 1997; 6: 103114.
  • 60
    Martin VM, Siewert C, Scharl A, Harms T, Heinze R, Ohl S, Radbruch A, Miltenyi S, Schmitz J. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. Exp Hematol 1998; 26: 252264.
  • 61
    Schmidt CM, Settle SL, Keene JL, Westlin WF, Nickols GA, Griggs DW. Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry. Clin Exp Metastasis 1999; 17: 537544.
  • 62
    Gross HJ, Verwer B, Houck D, Hoffman RA, Recktenwald D. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7). Proc Natl Acad Sci USA 1995; 92: 537541.
  • 63
    Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 1998; 95: 45894594.
  • 64
    Zabaglo L, Ormerod MG, Parton M, Ring A, Smith IE, Dowsett M. Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells. Cytometry 2003; 55A: 102108.